JP4362638B2 - ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法 - Google Patents

ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法 Download PDF

Info

Publication number
JP4362638B2
JP4362638B2 JP54960898A JP54960898A JP4362638B2 JP 4362638 B2 JP4362638 B2 JP 4362638B2 JP 54960898 A JP54960898 A JP 54960898A JP 54960898 A JP54960898 A JP 54960898A JP 4362638 B2 JP4362638 B2 JP 4362638B2
Authority
JP
Japan
Prior art keywords
inh
lps
cells
induced
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP54960898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002502367A5 (https=
JP2002502367A (ja
Inventor
クン，アーネスト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/855,616 external-priority patent/US5908861A/en
Application filed by Octamer Inc filed Critical Octamer Inc
Publication of JP2002502367A publication Critical patent/JP2002502367A/ja
Publication of JP2002502367A5 publication Critical patent/JP2002502367A5/ja
Application granted granted Critical
Publication of JP4362638B2 publication Critical patent/JP4362638B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
JP54960898A 1997-05-13 1998-05-13 ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法 Expired - Fee Related JP4362638B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/855,616 1997-05-13
US08/855,616 US5908861A (en) 1997-05-13 1997-05-13 Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US09/056,396 1998-04-06
US09/056,396 US6303629B1 (en) 1997-05-13 1998-04-06 Methods for treating inflammation, inflammatory diseases, arthritis and stroke using pADPRT inhibitors
PCT/US1998/010033 WO1998051308A1 (en) 1997-05-13 1998-05-13 METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009119631A Division JP2009227681A (ja) 1997-05-13 2009-05-18 ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法

Publications (3)

Publication Number Publication Date
JP2002502367A JP2002502367A (ja) 2002-01-22
JP2002502367A5 JP2002502367A5 (https=) 2005-12-08
JP4362638B2 true JP4362638B2 (ja) 2009-11-11

Family

ID=26735288

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54960898A Expired - Fee Related JP4362638B2 (ja) 1997-05-13 1998-05-13 ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法

Country Status (9)

Country Link
EP (1) EP1009404A4 (https=)
JP (1) JP4362638B2 (https=)
CN (1) CN1198614C (https=)
AU (2) AU7484798A (https=)
BR (1) BR9809115A (https=)
CA (1) CA2289119C (https=)
IL (1) IL132758A0 (https=)
NZ (1) NZ501650A (https=)
WO (2) WO1998051307A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
WO2002090334A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
CN101233121A (zh) * 2005-06-10 2008-07-30 彼帕科学公司 Parp调节剂和癌症的治疗
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
CN101534836B (zh) * 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EA026578B1 (ru) 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
CA2737400C (en) 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010061908A1 (ja) 2008-11-28 2010-06-03 中外製薬株式会社 １－（２ｈ）－イソキノロン誘導体
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND THEIR USES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004663A1 (en) * 1989-09-26 1991-04-18 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5482975A (en) 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
DE4436127A1 (de) 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
US10766598B2 (en) 2017-06-14 2020-09-08 The Boeing Company Wing-to-fuselage joints and aircraft including the same

Also Published As

Publication number Publication date
WO1998051308A1 (en) 1998-11-19
NZ501650A (en) 2001-11-30
AU7484798A (en) 1998-12-08
WO1998051307A1 (en) 1998-11-19
CA2289119A1 (en) 1998-11-19
IL132758A0 (en) 2001-03-19
EP1009404A1 (en) 2000-06-21
EP1009404A4 (en) 2009-07-01
AU745790B2 (en) 2002-03-28
CN1261278A (zh) 2000-07-26
JP2002502367A (ja) 2002-01-22
AU7492698A (en) 1998-12-08
CA2289119C (en) 2011-03-15
CN1198614C (zh) 2005-04-27
BR9809115A (pt) 2002-01-02

Similar Documents

Publication Publication Date Title
JP4362638B2 (ja) ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法
JP2009227681A (ja) ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法
Chou et al. Impact of intracellular innate immune receptors on immunometabolism
Gasse et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis
Kotanidou et al. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice
Uhlig et al. Phosphoinositide 3-OH kinase inhibition prevents ventilation-induced lung cell activation
Di Paola et al. Protective effects of ultramicronized palmitoylethanolamide (PEA-um) in myocardial ischaemia and reperfusion injury in vivo
Zhang et al. Protective Effects of Oroxylin A Against Doxorubicin‐Induced Cardiotoxicity via the Activation of Sirt1 in Mice
BRPI0616344A2 (pt) mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
US20110244059A1 (en) Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
Minodier et al. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients
Dravid et al. Resolvin D1‐loaded nanoliposomes promote M2 macrophage polarization and are effective in the treatment of osteoarthritis
CA3101274A1 (en) Use of neutrophil elastase inhibitors in liver disease
Chen et al. Esculetin rebalances M1/M2 macrophage polarization to treat sepsis‐induced acute lung injury through regulating metabolic reprogramming
Tao et al. Exploring the mechanism through which Phyllanthus emblica L. Extract exerts protective effects against acute gouty arthritis: a network pharmacology study and experimental validation
Ponnappa et al. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-α in rats
Batiha et al. Management of SARS-CoV-2 infection: key focus in macrolides efficacy for COVID-19
Badanthadka et al. Imiquimod-induced psoriasis mice model: a promising tool for psoriasis research?
Chen et al. Oxidative stress-mediated programmed cell death: a potential therapy target for atherosclerosis
Zhang et al. Targeted deletion of NF-κB p50 diminishes the cardioprotection of histone deacetylase inhibition
Shi et al. Endotoxin tolerance ameliorates lipopolysaccharide/D-galactosamine-induced acute liver failure by negative regulation of the NF-κB/NLRP3 and activation of Nrf2/HO-1 via Sitr1
Wu et al. Targeting IRE1α improves insulin sensitivity and thermogenesis and suppresses metabolically active adipose tissue macrophages in male obese mice
Chen et al. Inhibition of cytokine‐induced JAK‐STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acid
Zheng et al. The role of hypoxic microenvironment in rheumatoid arthritis
Li et al. Dose–effect of irbesartan on cyclooxygenase-2 and matrix metalloproteinase-9 expression in rabbit atherosclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090630

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090730

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120828

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120828

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120828

Year of fee payment: 3

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130828

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees